The companies will add US production of Lilly’s prefilled KwikPen devices near Cincinnati, with full operations expected in early 2027.
Eli Lilly and Company and manufacturing partner Resilience are investing $750 million to expand pharmaceutical production in the Cincinnati, Ohio, region.
The project will add US production of Lilly’s KwikPen, a prefilled injection device used with some of the company’s diabetes and obesity medicines. Site preparation is underway, with full operations expected to begin in early 2027.
The expansion is expected to create at least 400 skilled jobs in manufacturing, operations, quality and related areas. Resilience said the project will bring the number of jobs it has created across Ohio to more than 1,400.
Get industry leading pharma and biotech news, events and expert insights delivered to your inbox.
Ohio is also investing in the workforce needed to support pharmaceutical manufacturing growth. In March, New Albany was selected as the first site for the Ohio Life Science Training Center, backed by up to $30 million from JobsOhio and $5 million from the city. The center will prepare entry-level workers for roles in regulated manufacturing, production and laboratory operations. Although based near Columbus, it is intended to support life sciences employers across the state.
Resilience is a contract development and manufacturing organization (CDMO) that employs nearly 1,000 people across two facilities in the Cincinnati region.
Lilly and Resilience have worked together since 2023, producing more than 150 million doses of Lilly medicines for US patients.
According to a recent Reuters report, second-quarter sales of Lilly’s injectable diabetes and obesity medicines Mounjaro and Zepbound reached nearly $14.9 billion combined.
The Lilly-Resilience expansion is part of a broader wave of pharma investment across Ohio. In June, Resilience announced plans to move its global headquarters from San Diego to Blue Ash, a project expected to add about 200 jobs.
Hikma Pharmaceuticals also announced a $267 million investment across its Columbus and Bedford facilities, creating 350 jobs and expanding production of oral medicines, nasal products and sterile injectables.
These projects are expanding Ohio’s pharmaceutical manufacturing network across medicine production, device assembly, packaging and distribution.
If you want your company to be featured on Xtalks.com, please email [email protected].
Join or login to leave a comment
JOIN LOGIN